Sensodyne maker Haleon’s annual profits rose in line with expectations last year as it got a boost in demand for its oral hygeine and multivitamin products.
The business, spun off from drugmaker GSK in 2022, saw operating profit rise 10.5% to £2.5bn in the year to 31 December, matching analysts’ expectations.
Revenue slipped 0.6% to £11.2bn, also in line with analysts’ estimates.
Haleon’s power brands like Sensodyne toothpaste and Centrum multivitamins saw sales grow 6.3%, partially offsetting declines across pain relief and respiratory health.
Oral health sales were up 5.6% last year due to innovation and geographic expansion and now make up almost a third of sales. Sensodyne, its biggest brand, launched Clinical White, which has now been launched in over 10 markets including the US, UK and France.
“We are delivering against our growth plans, achieving 5.0% organic revenue growth for the year with organic profit growth ahead of this at 9.8%,” said CEO Brian McNamara.
“Importantly, 71% of our business gained or maintained share in the year, demonstrating the strength and appeal our brands continue to have with consumers around the world.”
In pain relief, revenue declined 3.3%, reflecting tough comparatives from 2023 when Haleon saw strong demand for Fenbid in China after the lifting of Covid restrictions. Advil revenue also fell last year as it lost listings in key retailers.
Haleon expects organic revenue to grow between 4% and 6% in 2025.
It has allocated £500m for share buybacks for the year.
No comments yet